Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone, Tirelizumab, and Bevacizumab in Advanced TNBC
NCT06125080Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in triple-negative breast cancer (TNBC). Started Oct 2023; status: recruiting.
02
Drugs
utidelone
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06125080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125080.